Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Tuesday, February 28, 2023 at 5:00 PM ET to report its fourth quarter and full year 2022 financial results and provide a corporate update.

In order to participate in the conference call, please register using the conference link here. The live webcast can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website beginning approximately two hours after the event.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer and autoimmune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Matthew Guido
Stern Investor Relations, Inc.
212-362-1200
matthew.guido@sternir.com

Staff

Recent Posts

Genflow Biosciences PLC Announces Holding(s) in Company – 2

TR-1: Standard form for notification of major holdings LONDON, UNITED KINGDOM / ACCESSWIRE / January…

8 minutes ago

Genflow Biosciences PLC Announces Holding(s) in Company – 1

TR-1: Standard form for notification of major holdings LONDON, UNITED KINGDOM / ACCESSWIRE / January…

8 minutes ago

Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2025

– Revenue of $1,021.8 Million Grows 0.9% -- -- Revenue Increases 1.0% on Constant Currency…

9 hours ago

MaryRuth’s Celebrates TikTok Shop Super Brand Day With Exclusive Offers and Viral Favorites

LOS ANGELES, Jan. 12, 2025 /PRNewswire/ -- MaryRuth's, the trusted leader in liquid vitamins and…

15 hours ago

Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million

Preliminary unaudited product revenue for the fourth quarter of 2024 is expected to be approximately…

18 hours ago

Lipozem: Introducing Lipozem as the Bizarre Turmeric Hack for Weight Loss Support

LAKELAND, Fla., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Lipozem emerges in an era where weight…

18 hours ago